This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Stock Reports for Exxon Mobil, Texas Instruments & GlaxoSmithKline
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), Texas Instruments (TXN), and GlaxoSmithKline (GSK).
Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on
by Debanjana Dey
These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.
Edwards Lifesciences (EW) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on its promising Surgical Structural Heart business and bullish 2021 guidance.
Top Stock Reports for Texas Instruments, CSX & Norfolk Southern
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Incorporated (TXN), CSX Corporation (CSX), and Norfolk Southern Corporation (NSC).
Edwards Lifesciences (EW) Down 4.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Research Reports for JPMorgan, Home Depot & Merck
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), The Home Depot (HD), and Merck (MRK).
Edwards Lifesciences (EW) Surges 6.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Edwards Lifesciences (EW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Edwards Lifesciences (EW) Beats on Q1 Earnings, Margins Down
by Zacks Equity Research
Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust segmental performances in Q1.
Edwards Lifesciences (EW) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 14.89% and 4.93%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Until we have nano-bots to cruise our blood vessels, the catheter remains mightier than the scalpel
Flight Plan for Trading: Market Lessons from My Pilot Dad
by Kevin Cook
Learning to fly an airplane can build an excellent structured thought process for navigating markets.
Analysts Estimate Edwards Lifesciences (EW) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?
by Zacks Equity Research
Continued strength in the adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q1 revenues.
Top Analyst Reports for Facebook, Adobe & Novo Nordisk
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Adobe (ADBE), and Novo Nordisk (NVO).
Bull of the Day: Penumbra (PEN)
by Kevin Cook
Leader in treating stroke with catheter-based technology has fully recovered from a product recall
Q4 Earnings Season Scorecard and Research Reports for Toyota, PepsiCo & BlackRock
by Sheraz Mian
We have provided a real-time update on the Q4 earnings season, in addition to featuring new research reports on 16 major stocks in today's Research Daily.
Edwards Lifesciences (EW) Q4 Earnings Fall Shy of Estimates
by Zacks Equity Research
Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust performances in TMTT business in Q4.
Edwards Lifesciences (EW) Q4 Earnings Lag Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of -5.66% and 0.71%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
5 Must-See Large Cap Earnings Charts
by Tracey Ryniec
While technology stocks remain hot in 2021, there are other sectors that should be on your radar this earnings season.
Top Analyst Reports for Walmart, Intel & Cisco
by Sheraz Mian
Today's Research Daily features new research reports on 12 major stocks, including Walmart (WMT), Intel (INTC), and Cisco Systems (CSCO).
What's in Store for Edwards Lifesciences in (EW) Q4 Earnings?
by Zacks Equity Research
Robust customer adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve is likely to have driven Edwards Lifesciences' (EW) Q4 revenues.
Bear of the Day: Penumbra (PEN)
by Kevin Cook
Revolutionary catheter-based treatment for stroke events encounters device problems and a recall
3 Best Buys from the Prospering Medical Instruments Industry
by Urmimala Biswas
Despite the challenges posed by the COVID-19 pandemic, higher demand for lab-testing products, digital influence, and AI and robotics is likely to lend support to the Zacks Medical - Instruments industry. TMO, IDXX and STE are well positioned to gain.